Phio Pharmaceuticals Corp. (PHIO) - Form 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K was filed by Phio Pharmaceuticals Corp. on July 7, 2025. The filing announces the scheduling of the Company's 2025 Annual Meeting of Stockholders and provides updated deadlines for stockholder proposals and director nominations.
Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on corporate governance events and does not contain financial performance data.
Material Changes
The primary material change is the rescheduling of the 2025 Annual Meeting of Stockholders to September 11, 2025. This date is more than 30 days from the anniversary of the 2024 Annual Meeting, which necessitates revised deadlines for stockholder proposals under Rule 14a-8 and universal proxy rules.
Guidance, Outlook, and Management Commentary
- Meeting Date: September 11, 2025.
- Record Date: Stockholders of record at the close of business on July 18, 2025, are entitled to vote.
- Proposal Deadlines: Written notice of stockholder proposals under Rule 14a-8 must be received by 5:00 p.m. (Eastern Time) on July 17, 2025.
- Director Nominations: Direct nominations or proposals not included in proxy materials must also be delivered by July 17, 2025.
- Universal Proxy: Notice for proxy solicitations under Rule 14a-19 is due by July 17, 2025.
- Future Filings: Time, location, and other details will be included in the definitive proxy statement to be filed prior to the meeting.
Key Facts for Investor Verification
- Verify the record date of July 18, 2025, to determine voting eligibility.
- Confirm the July 17, 2025, deadline for submitting stockholder proposals or director nominations.
- Monitor the upcoming definitive proxy statement for the specific time and location of the September 11, 2025, meeting.
- Note that adjournment or postponement of the meeting will not extend the submission deadlines.